Northwell Health Cancer Institute seamlessly integrates Northwell’s world-class hospitals, innovative treatments and leading cancer specialists of every kind. We’re dedicated to cancer prevention, screening, diagnosis, treatment, research and survivorship. Our disease-focused, multidisciplinary teams provide holistic care, treating patients’ cancer, as well as working with colleagues in disciplines throughout Northwell to treat any other existing medical conditions. Our experts provide comprehensive, compassionate care through innovative clinical trials, state-of-the-art medical and radiation oncology treatments and leading edge surgical techniques. More New Yorkers choose Northwell for cancer care than any other health system —which means you have access to the most experienced cancer fighters in the state.
Experts share treatment experiences with osimertinib and afatinib, the potential role of immunotherapy, and ongoing investigations with ADCs and emerging TKIs for patients with uncommon EGFR mutations.
Insights into how the UNICORN study, which assessed osimertinib, is impacting treatment decisions for uncommon EGFR mutations, and other ongoing trials shedding light on effective treatments for this patient population.
Expert insights on sequencing treatment options for patients with uncommon EGFR mutations who have progressed on afatinib, emphasizing clinical trial considerations, biomarker testing, and emerging therapeutic approaches.
Explore dosing nuances and adverse event management strategies for afatinib in treating EGFR mutant non-small cell lung cancer, reflecting real-world practices and clinical insights.
Panelists discuss the intricacies of treating uncommon EGFR mutations, dissecting approved treatment options, considerations for specific mutations, and insights into the evolving drug landscape.
Explore the complexity of uncommon EGFR mutations in lung cancer with experts discussing classifications, testing methodologies, and the necessity of comprehensive panels for accurate identification.
Delve into the evolving landscape of treating EGFR mutations in lung cancer, exploring emerging therapies, structural classifications, and the complexity of individual mutation responses.
The impact of and strategies for addressing less frequent mutations in NSCLC treatment decisions, emphasizing actionable alterations and timely interventions in challenging scenarios.
Expert perspectives on improving turnaround times in genomic testing for lung cancer, covering strategies, challenges, and the significance of liquid biopsy in optimizing patient care.
Shared insight into strategies in genomic testing for lung cancer, emphasizing the importance of comprehensive next-generation sequencing, DNA vs. RNA sequencing, and the evolving role of liquid biopsy.
Experts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.
Francisco Javier Esteva, MD, PhD, discusses key findings from the phase 3 NATALEE trial in patients with hormone receptor–positive, HER2-negative early breast cancer.
Daniel King, MD, PhD, discusses the results of an institutional review evaluating socioeconomic factors associated with disparities for germline genetic testing in patients with pancreatic adenocarcinoma, why germline testing is necessary for thi population, and how he is addressing gaps in germline testing in his own practice.
Francisco Javier Esteva, MD, PhD, discusses the clinical implications of the fixed-dose regimen comprised of subcutaneous trastuzumab and pertuzumab in the treatment of patients with HER2-positive breast cancer.
Paul Lawrence Baron, MD, discussed best practices for determining a patient’s risk of developing breast cancer, the significance of targeting HER2 in patients with early-stage and metastatic disease, and remaining questions with radiation therapy in the field.
Francisco Javier Esteva, MD, PhD, discussed the current approach to treating patients with early-stage HER2-positive breast cancer, unmet needs in the space, and future directions with neratinib and T-DM1.